LivaNova Reports Q1 2026 Earnings and Updates Revenue Guidance
LivaNova reported Q1 2026 earnings with consolidated revenue of $362 million, showing 11% constant-currency growth. The company raised its full-year revenue guidance to 7%-8% from 6%-7%, driven by strong performance in both the Cardiopulmonary and Epilepsy segments. Adjusted gross margin slightly declined to 68%.
Tickers: $LIVN